Thr325Ile polymorphism of the TAFI gene is related to TAFI antigen plasma levels and angiographic restenosis after percutaneous coronary interventions.
BACKGROUND
The fibrinolytic system is closely related to several processes that are involved in restenosis. We have previously shown that high pre-procedural plasma levels of thrombin-activatable fibrinolysis inhibitor (TAFI) antigen predicted angiographic restenosis. The aims of this study were to evaluate the relationship between Thr325Ile polymorphisms, plasma levels of TAFI antigen, and late angiographic restenosis after percutaneous coronary intervention (PCI).


METHODS
We prospectively studied 159 patients with stable angina who underwent successful elective angioplasty or stenting of de novo native coronary artery lesions. Blood samples were drawn before the procedure. TAFI antigen levels were measured, as well as the presence of TAFI Ile325Thr genetic variation. Follow-up coronary angiography was performed in 90% of patients.


RESULTS
The genotypes based on Ile325Thr substitution had significantly different TAFI antigen levels: genotype C/C>C/T>T/T (111+/-29%, 87+/-24%, and 59+/-22%, respectively, p<0.006). T/T genotype was associated with lower rates of restenosis compared to C/T and C/C genotypes (25% versus 37% and 33%, respectively, p<0.05).


CONCLUSIONS
These data suggest that plasma TAFI antigen levels are genetically controlled. The T/T Thr325Ile polymorphism of the TAFI gene is associated with lower plasma levels of TAFI antigen and lower restenosis rates after PCI.
The Roy and Ann Foss Cardiovascular Research Program, Division of Cardiology, Terrence Donnelly Heart Center, St. Michael's Hospital, 30 Bond Street, University of Toronto, Toronto, Ontario M5B 1W8, Canada.
Amit
A
Segev
Robert A
RA
Hegele
Herbert K
HK
Lau
John D
JD
Sparkes
Jerome M
JM
Teitel
Robert J
RJ
Chisholm
Bradley H
BH
Strauss
D015906:Angioplasty, Balloon, Coronary / Q000706:statistics & numerical data*; D000941:Antigens / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D002170:Canada / Q000453:epidemiology; D025901:Carboxypeptidase B2 / Q000097:blood* / Q000235:genetics*; D005260:Female; D020022:Genetic Predisposition to Disease / Q000453:epidemiology*; D005820:Genetic Testing / Q000379:methods; D006083:Graft Occlusion, Vascular / Q000097:blood* / Q000000981:diagnostic imaging / Q000453:epidemiology* / Q000235:genetics; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011110:Polymorphism, Genetic; D011859:Radiography; D018570:Risk Assessment / Q000379:methods; D012307:Risk Factors; D017678:Sex Distribution
D000941:Antigens; D015415:Biomarkers; D025901:Carboxypeptidase B2